Journal of Gastroenterology

, Volume 44, Issue 7, pp 793–798 | Cite as

Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma

  • Masato Narita
  • Etsuro Hatano
  • Shigeki Arizono
  • Aya Miyagawa-Hayashino
  • Hiroyoshi Isoda
  • Koji Kitamura
  • Kojiro Taura
  • Kentaro Yasuchika
  • Takashi Nitta
  • Iwao Ikai
  • Shinji Uemoto
Rapid Communication

Abstract

Background

Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) is an MRI contrast agent with perfusion and hepatoselective properties. The purpose of the study was to examine uptake of Gd-EOB-DTPA in the hepatobiliary phase in hepatocellular carcinoma (HCC).

Methods

A retrospective analysis of 22 patients with HCC who underwent preoperative Gd-EOB-DTPA-enhanced MRI was performed. Enhancement ratios (ERs) and expression levels of the organic anion transporter (OATP) 1B3 protein were examined.

Results

Gd-EOB-DTPA accumulated in the hepatobiliary phase in 6 of the 22 cases. All 6 Gd-EOB-DTPA-positive cases were moderately differentiated HCC, but 11 other moderately differentiated HCCs did not show Gd-EOB-DTPA uptake. Histopathologically, 4 Gd-EOB-DTPA-positive HCCs and 5 Gd-EOB-DTPA-negative HCCs produced bile. HCCs with Gd-EOB-DTPA uptake overexpressed OATP1B3 compared with HCCs without Gd-EOB-DTPA uptake, and OATP1B3 levels were significantly correlated with ERs (r = 0.91, P < 0.0001).

Conclusions

Uptake of Gd-EOB-DTPA in HCC is determined by expression of OATP1B3 rather than by tumor differentiation or bile production.

Keywords

Green hepatoma Gd-EOB-DTPA MRI OATP1B3 HCC 

References

  1. 1.
    Semelka RC, Helmberger TK. Contrast agents for MR imaging of the liver. Radiology. 2001;218:27–38.PubMedGoogle Scholar
  2. 2.
    Hamm B, Staks T, Muhler A, Bollow M, Taupitz M, Frenzel T, et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology. 1995;195:785–92.PubMedGoogle Scholar
  3. 3.
    Vogl TJ, Kummel S, Hammerstingl R, Schellenbeck M, Schumacher G, Balzer T, et al. Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology. 1996;200:59–67.PubMedGoogle Scholar
  4. 4.
    Reimer P, Rummeny EJ, Shamsi K, Balzer T, Daldrup HE, Tombach B, et al. Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence. Radiology. 1996;199:177–83.PubMedGoogle Scholar
  5. 5.
    Zech CJ, Herrmann KA, Reiser MF, Schoenberg SO. MR imaging in patients with suspected liver metastases: value of liver-specific contrast agent Gd-EOB-DTPA. Magn Reson Med Sci. 2007;6:43–52.PubMedCrossRefGoogle Scholar
  6. 6.
    Ichikawa T. MRI in the evaluation of hepatocellular nodules: role of pulse sequences and contrast agents. Intervirology. 2004;47:252–70.PubMedCrossRefGoogle Scholar
  7. 7.
    Huppertz A, Haraida S, Kraus A, Zech CJ, Scheidler J, Breuer J, et al. Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT—initial observations. Radiology. 2005;234:468–78.PubMedCrossRefGoogle Scholar
  8. 8.
    Saito K, Kotake F, Ito N, Ozuki T, Mikami R, Abe K, et al. Gd-EOB-DTPA enhanced MRI for hepatocellular carcinoma: quantitative evaluation of tumor enhancement in hepatobiliary phase. Magn Reson Med Sci. 2005;4:1–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Scheuer PJ, Lefkowitch JH. Liver biopsy interpretation. 7th edn. Philadelphia: WB Saunders; 2006.Google Scholar
  10. 10.
    Fujita M, Yamamoto R, Takahashi M, Tsuji T, Yamanaka T, Miyazawa T, et al. Paradoxic uptake of Gd-EOB-DTPA by hepatocellular carcinoma in mice: quantitative image analysis. J Magn Reson Imaging. 1997;7:768–70.PubMedCrossRefGoogle Scholar
  11. 11.
    Ni Y, Marchal G, Yu J, Muhler A, Lukito G, Baert AL. Prolonged positive contrast enhancement with Gd-EOB-DTPA in experimental liver tumors: potential value in tissue characterization. J Magn Reson Imaging. 1994;4:355–63.PubMedCrossRefGoogle Scholar
  12. 12.
    Konig J, Seithel A, Gradhand U, Fromm MF. Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch Pharmacol. 2006;372:432–43.PubMedCrossRefGoogle Scholar
  13. 13.
    van Montfoort JE, Stieger B, Meijer DK, Weinmann HJ, Meier PJ, Fattinger KE. Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by the organic anion transporting polypeptide Oatp1. J Pharmacol Exp Ther. 1999;290:153–7.PubMedGoogle Scholar
  14. 14.
    Libra A, Fernetti C, Lorusso V, Visigalli M, Anelli PL, Staud F, et al. Molecular determinants in the transport of a bile acid-derived diagnostic agent in tumoral and nontumoral cell lines of human liver. J Pharmacol Exp Ther. 2006;319:809–17.PubMedCrossRefGoogle Scholar
  15. 15.
    Pascolo L, Petrovic S, Cupelli F, Bruschi CV, Anelli PL, Lorusso V, et al. Abc protein transport of MRI contrast agents in canalicular rat liver plasma vesicles and yeast vacuoles. Biochem Biophys Res Commun. 2001;282:60–6.PubMedCrossRefGoogle Scholar
  16. 16.
    Borst P, Elferink RO. Mammalian ABC transporters in health and disease. Annu Rev Biochem. 2002;71:537–92.PubMedCrossRefGoogle Scholar
  17. 17.
    Abe T, Unno M, Onogawa T, Tokui T, Kondo TN, Nakagomi R, et al. LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology. 2001;120:1689–99.PubMedCrossRefGoogle Scholar
  18. 18.
    Smith NF, Acharya MR, Desai N, Figg WD, Sparreboom A. Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther. 2005;4:815–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2009

Authors and Affiliations

  • Masato Narita
    • 1
  • Etsuro Hatano
    • 1
  • Shigeki Arizono
    • 2
  • Aya Miyagawa-Hayashino
    • 3
  • Hiroyoshi Isoda
    • 2
  • Koji Kitamura
    • 1
  • Kojiro Taura
    • 1
  • Kentaro Yasuchika
    • 1
  • Takashi Nitta
    • 1
  • Iwao Ikai
    • 1
  • Shinji Uemoto
    • 1
  1. 1.Department of Surgery, Graduate School of MedicineKyoto UniversityKyotoJapan
  2. 2.Department of Diagnostic Imaging and Nuclear Medicine, Graduate School of MedicineKyoto UniversityKyotoJapan
  3. 3.Department of Diagnostic PathologyKyoto University HospitalKyotoJapan

Personalised recommendations